Research programme: rare genetic disease therapeutics - Blueprint Medicines

Drug Profile

Research programme: rare genetic disease therapeutics - Blueprint Medicines

Alternative Names: ALK-2 targeting therapeutics - Blueprint Medicines

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blueprint Medicines
  • Class Small molecules
  • Mechanism of Action Activin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Fibrodysplasia ossificans progressiva

Most Recent Events

  • 27 Jul 2017 Alexion terminates research and development agreement with Blueprint Medicines for therapeutics targeting ALK-2 while still retaining their commercialisation rights (Blueprint Medicines pipeline, July 2017)
  • 27 Jul 2017 Research programme: rare genetic disease therapeutics - Blueprint Medicines is available for licensing as of 27 Jul 2017. http://www.blueprintmedicines.com/pipeline/
  • 03 Mar 2015 Protein kinase modulators licensed to Alexion pharmaceuticals worldwide for the treatment of Inborn genetic disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top